Company intelligence / Profile preview

Claris Bio

Jersey City, New Jersey, United Statescrunchbase.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 3

Overview

Currently investigating the safety and efficacy of its topical ocular biologic dHGF in a randomized, controlled, double-masked study (CSB-C20-003, NCT04909450) in patients with stage 2 and 3 neurotrophic keratitis. Late-stage data was expected in the first half of 2024.

Therapeutic areas: Ophthalmology
Modalities: Recombinant protein
Industry: Biotech

Drug pipeline

1 asset

dHGF

Partnerships

Kringle PharmaMassachusetts Eye and Ear Infirmary (MEEI)

Beyond the preview

Go deeper on Claris Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Claris Bio.

Explore the full profile